NASDAQ:GERN

Geron Stock Insider Trading

Healthcare > Biotechnology

Buy GERN

*Your capital is at risk

$1.16

-0.0100 (-0.85%)

At Close: Jun 03, 2026

Geron Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be positive at 89.02. In total, the insiders bought 58.31M and sold 1.36M GERN shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	89.02
● Buy	58.31M shares
● Sell	1.36M shares
97% Buy Activity Strong Negative Correlation
Buy Signal High Confidence May 26, 2026 Analysis Breakdown: Strongly supported by a very high Insider Power Score of 89.02. Confidence increased due to high data reliability score of 100. Supported by overwhelming buy-side pressure (97% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 20, 2026 Buy	Stock Option (right to buy) A-Award	Bir Dawn Carter Director	Director	220 000 Value: $277.2K
May 20, 2026 Buy	Stock Option (right to buy) A-Award	O'farrell Elizabeth G. Director	Director	220 000 Value: $277.2K
May 20, 2026 Buy	Stock Option (right to buy) A-Award	Spiegel Robert J. Director	Director	220 000 Value: $277.2K
May 20, 2026 Buy	Stock Option (right to buy) A-Award	Molineaux Susan Director	Director	220 000 Value: $277.2K
May 20, 2026 Buy	Stock Option (right to buy) A-Award	Mcdonald John F Director	Director	220 000 Value: $277.2K
Apr 13, 2026 Buy	Common Stock J-Other	Williams Timothy Insider	Other	0 Value: $0
Apr 13, 2026 Buy	Stock Option (Right to Buy) A-Award	Williams Timothy EVP And Chief Legal Officer	Officer	2 500 000 Value: $4.33M
Mar 31, 2026 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	5 243 Value: $8K
Mar 25, 2026 Buy	Common Stock J-Other	Andrews Patricia S Insider	Other	0 Value: $0
Mar 25, 2026 Buy	Stock Option (Right to Buy) A-Award	Andrews Patricia S Director	Director	270 000 Value: $423.9K
Mar 25, 2026 Buy	Common Stock J-Other	Chinoporos Constantine Insider	Other	0 Value: $0
Mar 25, 2026 Buy	Stock Option (Right to Buy) A-Award	Chinoporos Constantine Director	Director	270 000 Value: $423.9K
Feb 18, 2026 Sell	Common Stock S-Sale	Robertson Michelle EVP, Chief Financial Officer	C-Suite Officer	9 855 Value: $19.1K
Feb 18, 2026 Buy	Restricted Stock Units M-Exempt	Robertson Michelle EVP, Chief Financial Officer	C-Suite Officer	27 500 Value: $53.4K
Feb 18, 2026 Buy	Common Stock M-Exempt	Robertson Michelle EVP, Chief Financial Officer	C-Suite Officer	27 500 Value: $53.4K
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Eid Joseph EVP, R&d; Chief Medical Office	Officer	2 220 000 Value: $4.00M
Feb 17, 2026 Buy	Stock Option (Right to Buy) A-Award	Robertson Michelle EVP, Chief Financial Officer	C-Suite Officer	1 660 000 Value: $2.99M
Dec 31, 2025 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	5 918 Value: $8K
Oct 20, 2025 Buy	Stock Option (right to buy) A-Award	Elnawawi Ahmed EVP, Chief Commercial Officer	Officer	3 000 000 Value: $3.81M
Oct 20, 2025 Buy	Common Stock	Elnawawi Ahmed EVP, Chief Commercial Officer	Officer	0 Value: $0
Sep 30, 2025 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	5 702 Value: $8K
Sep 30, 2025 Buy	Common Stock A-Award	Spiegel Robert J. Director	Director	5 702 Value: $8K
Aug 07, 2025 Buy	Stock Option (right to buy) A-Award	Semerjian Harout President And CEO	CEO / President	7 000 000 Value: $9.10M
Aug 07, 2025 Buy	Stock Option (right to buy) A-Award	Semerjian Harout President And CEO	CEO / President	4 000 000 Value: $5.20M
Aug 07, 2025 Buy	Common Stock J-Other	Semerjian Harout President And CEO	CEO / President	0 Value: $0

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT GERON CORPORATION

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hematologic myeloid malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes a...

Read Full Profile Here